TVGN

Company Overview — What Does Tevogen Bio Holdings Inc. Do?

Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company was founded in 2020 and is based in Warren, New Jersey. Tevogen Bio Holdings Inc. (TVGN) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Ryan Saadi and employs approximately 3 people. With a market capitalization of $18M, TVGN is one of the notable companies in the Healthcare sector.

Tevogen Bio Holdings Inc. (TVGN) Stock Rating — Reduce (April 2026)

As of April 2026, Tevogen Bio Holdings Inc. receives a Reduce rating with a composite score of 41.7/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TVGN ranks #2,493 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Tevogen Bio Holdings Inc. ranks #316 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TVGN Stock Price and 52-Week Range

Tevogen Bio Holdings Inc. (TVGN) currently trades at $5.73. The stock lost $0.13 (2.2%) in the most recent trading session. The 52-week high for TVGN is $10.76, which means the stock is currently trading -46.7% from its annual peak. The 52-week low is $0.17, putting the stock 3231.4% above its annual trough. Recent trading volume was 27K shares, suggesting relatively thin trading activity.

Is TVGN Overvalued or Undervalued? — Valuation Analysis

Tevogen Bio Holdings Inc. (TVGN) carries a value factor score of 9/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth.

At current multiples, Tevogen Bio Holdings Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Tevogen Bio Holdings Inc. Profitability — ROE, Margins, and Quality Score

Tevogen Bio Holdings Inc. (TVGN) earns a quality factor score of 32/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 443.0%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at -627.0% versus the sector average of -33.1%.

Revenue growth is running at -1039100.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TVGN Debt, Balance Sheet, and Financial Health

Tevogen Bio Holdings Inc. has a debt-to-equity ratio of -21.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 0.22x, which may signal near-term liquidity tightness. Total debt on the balance sheet is $2M. Cash and equivalents stand at $1M.

TVGN has a beta of -5.24, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Tevogen Bio Holdings Inc. is 27/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Tevogen Bio Holdings Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Tevogen Bio Holdings Inc. reported revenue of $-100,373 and earnings per share (EPS) of $-8.08. Net income for the quarter was $-27M. Operating income came in at $-28M.

In FY 2025, Tevogen Bio Holdings Inc. reported revenue of $-195,618 and earnings per share (EPS) of $-8.08. Net income for the quarter was $-26M. Operating income came in at $-26M.

In Q3 2025, Tevogen Bio Holdings Inc. reported revenue of $-62,340 and earnings per share (EPS) of $-0.03. Net income for the quarter was $-6M. Operating income came in at $-6M.

In Q2 2025, Tevogen Bio Holdings Inc. reported revenue of $-38,033 and earnings per share (EPS) of $-0.03. Net income for the quarter was $-6M. Revenue grew -633983.3% year-over-year compared to Q2 2024. Operating income came in at $-5M.

Over the past 8 quarters, Tevogen Bio Holdings Inc. has experienced revenue contraction from $6 to $-100,373. Investors analyzing TVGN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TVGN Dividend Yield and Income Analysis

Tevogen Bio Holdings Inc. (TVGN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TVGN Momentum and Technical Analysis Profile

Tevogen Bio Holdings Inc. (TVGN) has a momentum factor score of 80/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 40/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 41/100 reflects moderate short selling activity.

TVGN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Tevogen Bio Holdings Inc. (TVGN) ranks #316 out of 838 stocks based on the Blank Capital composite score. This places TVGN in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TVGN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TVGN vs S&P 500 (SPY) comparison to assess how Tevogen Bio Holdings Inc. stacks up against the broader market across all factor dimensions.

TVGN Next Earnings Date

No upcoming earnings date has been announced for Tevogen Bio Holdings Inc. (TVGN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TVGN? — Investment Thesis Summary

The quantitative profile for Tevogen Bio Holdings Inc. suggests caution. The quality score of 32/100 flags below-average profitability. The value score of 9/100 indicates premium valuation. Price momentum is positive at 80/100, suggesting the trend favors buyers. High volatility (stability score 27/100) increases portfolio risk.

In summary, Tevogen Bio Holdings Inc. (TVGN) earns a Reduce rating with a composite score of 41.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TVGN stock.

Related Resources for TVGN Investors

Explore more research and tools: TVGN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TVGN head-to-head with peers: TVGN vs AZN, TVGN vs SLGL, TVGN vs VMD.